Fabrice LAURENT |
||
Information |
||
Infectiology and Public Health UMR1282 INRA-Tours Univ | ||
Apicomplexa and Mucosal immunity (AIM laboratory) | ||
Tours/Nouzilly | ||
0000-0002-9687-7952 | ||
This email address is being protected from spambots. You need JavaScript enabled to view it. | ||
https://www6.val-de-loire.inrae.fr/infectiologie-santepublique_... | ||
@FabriceLaurent0 | ||
Scientific interests and projects |
||
General scientific interests: Apicomplexa and Mucosal Immunity (AIM) team is working on two apicomplexan parasites with intestinal tropism, Cryptosporidium and Eimeria. Historically our research on cryptosporidiosis mainly concerned investigations on the protective and pathological immune responses. However, we extend our researches and recently start to characterize the molecular mechanisms that govern Cryptosporidium/intestinal epithelial cell interactions and the long term consequences of the infection on intestinal homeostasis and immune disorders. In man and farm animals, cryptosporidiosis is poorly controlled and we wish to combine two complementary strategies for an efficient control of the disease. Based on strong dependence of functional immune responses for controlling Cryptosporidium we wish to develop immunostimulatory strategies dedicated to neonates in order to strengthen their ability to limit parasite growth. Drug therapies are limited both in human and livestock, we therefore aim to develop new potent molecules to control parasite development. Scientific activities to be developed in the framework of Parafrap: II- Gut physiopathology: Infection of young individuals by C. parvum induces a long-term defect on intestinal gut physiology and this has been linked to the occurrence of Irritable Bowel Syndrome (IBS). We plan to investigate the contribution of Paneth cells (PC) and their antimicrobial peptides on the onset of this intestinal disorder. III- Control strategies: In collaboration with several international teams including Ali Hakimi’s team from Parafrap with whom we recently identified a first promising target (CPSF3) we wish to further develop our therapeutic arsenal against Cryptosporidium, from drug screening to molecular target identification and in vivo final validation (rodent and large animal models). |
||
Top 5 publications of the last 5 years |
||
1. C. Swale, A. Bougdour, A. Gnahoui-David, J. Tottey, S. Georgeault, F. Laurent, A. Palencia and Mohamed-Ali Hakimi, Metal-captured inhibition of pre-mRNA processing activity by CPSF3 controls Cryptosporidium infection Science Translational Medicine, 11(517): eaax7161. doi: 10.1126/scitranslmed.aax7161 2. Potiron L, Lacroix-Lamandé S, Marquis M, Levern Y, Fort G, Franceschini I, Laurent F. Batf3-Dependent Intestinal Dendritic Cells Play a Critical Role in the Control of Cryptosporidium parvum Infection. J Infect Dis. 2019 Feb 23;219(6):925-935. doi: 10.1093/infdis/jiy528 3. Diallo MA, Sausset A, Gnahoui-David A, Silva ARE, Brionne A, Le Vern Y, Bussière FI, Tottey J, Lacroix-Lamandé S, Laurent F, Silvestre A. Eimeria tenella ROP kinase EtROP1 induces G0/G1 cell cycle arrest and inhibits host cell apoptosis. Cellular Microbiology. 2019 Jul;21(7):e13027. doi: 10.1111/cmi.13027. 4. Riba A, Olier M, Lacroix-Lamandé S, Lencina C, Bacquié V, Harkat C, Gillet M, Baron M, Sommer C, Mallet V, Salvador-Cartier C, Laurent F, Théodorou V, Ménard S. Microbiota dysbiosis induced by defect of Paneth cells triggers visceral hypersensitivity in mice. Gastroenterology. 2017 Dec;153(6):1594-1606.e2. doi: 10.1111/cmi.12632. 5. de Sablet T, Potiron L, Marquis M, Bussière FI, Lacroix-Lamandé S, Laurent F. Cryptosporidium parvum increases intestinal permeability through interaction with epithelial cells and IL-1β and TNFα released by inflammatory monocytes. Cell Microbiol. 2016 Dec;18(12):1871-1880. 10.1111/cmi.12632. |
Postdoctoral position, Institut Pasteur, Paris, France A 24-month post-doctoral position starting on March 1st 2025 and funded by the French National Research Agency (ANR) is available in the Trypanosome...
Postdoctoral positions, LPHI Lab, Montpellier, France Two ERC-funded (JANUS 2024-2029) postdoc positions are open in the lab to study cell cycle regulation in malaria...
Postdoctoral position, Institut Pasteur, Paris, France A postdoc position is available at the Institut Pasteur Paris, in the signalling and host-parasite interactions research group, headed by Dr Najma Rachidi...
ABOUT SPEAKERS PROGRAMME REGISTRATION CONTACT LOCATION About the workshop ParaFrap is organizing the ParaFrap Next Generation in Parasitology...
[Communiqué] As part of the actions of the Health Innovation Plan 2030, the health component of the France 2030 plan, Mohamed-Ali Hakimi is one of the 22 laureates of an Excellence Chair in Biology/Health, supported to conduct high-level research...
The York Biomedical Research Institute (YBRI) are hosting an online live seminar on Friday 24th May 1-2pm BST as part of their biomedical science seminar series. You are all welcome to attend - registration is required via the...
[Communiqué] Congratulations to Arthur Talman, IRD Research Leader in the MIVEGEC laboratory (Montpellier), who has been awarded an Advanced Grant from the European Research Council (ERC) for the project "TROJAN - Molecular mimicry and immune...
Ana Rita Gomes, a CNRS Research Associate at the Laboratory of Pathogens and Host Immunity in Montpellier, and former Postdoctoral fellow of the LabEx ParaFrap, has been awarded the prestigious CNRS Bronze Medal in 2023. This...
Happy New Year 2024! To kick off this new scientific year, here is the ParaFrap webinar schedule. Since January 2021, ParaFrap has been organizing a series of webinars. This monthly event, held every 2nd Thursday of the month, aims to strengthen...
The team of Dr. Mohamed-Ali Hakimi, in collaboration with Isabelle Coppens (Johns Hopkins University Bloomberg School of Public Health and Malaria Research Institute, Baltimore, MD, USA), has developed a new (epi)genetic method to produce in vitro...
© 2023. All rights reserved MLCOM
Notre site LabEx ParaFrap utilise des cookies pour réaliser des statistiques de visites, partager des contenus sur les réseaux sociaux et améliorer votre expérience. En refusant les cookies, certains services seront amenés à ne pas fonctionner correctement. Nous conservons votre choix pendant 30 jours. Vous pouvez changer d'avis en cliquant sur le bouton 'Cookies' en bas à gauche de chaque page de notre site. En savoir plus
Ce site utilise des cookies pour assurer son bon fonctionnement et ne peuvent pas être désactivés de nos systèmes. Nous ne les utilisons pas à des fins publicitaires. Si ces cookies sont bloqués, certaines parties du site ne pourront pas fonctionner.
Ce site utilise des cookies de mesure et d’analyse d’audience, tels que Google Analytics et Google Ads, afin d’évaluer et d’améliorer notre site internet.
Ce site utilise des composants tiers, tels que NotAllowedScript672cb111aa8deReCAPTCHA, Google NotAllowedScript672cb111aa46cMaps, MailChimp ou Calameo, qui peuvent déposer des cookies sur votre machine. Si vous décider de bloquer un composant, le contenu ne s’affichera pas
Des plug-ins de réseaux sociaux et de vidéos, qui exploitent des cookies, sont présents sur ce site web. Ils permettent d’améliorer la convivialité et la promotion du site grâce à différentes interactions sociales.
Ce site web utilise un certain nombre de cookies pour gérer, par exemple, les sessions utilisateurs.